Massimo Santoro

Q: What Schools Are Affiliated With Massimo Santoro

Massimo Santoro is affiliated with the following schools: Università degli Studi della Campania Luigi Vanvitelli, University of Sydney, University of Naples Federico II

Massimo Santoro's AcademicInfluence.com Rankings

Massimo Santoro

Philosophy

#8351

World Rank

#11710

Historical Rank

Logic

#5384

World Rank

#6778

Historical Rank

philosophy Degrees

Massimo Santoro

Biology

#11288

World Rank

#14673

Historical Rank

Endocrinology

#166

World Rank

#178

Historical Rank

Molecular Biology

#1728

World Rank

#1757

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Massimo Santoro Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Massimo Santoro's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015) (1442)
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. (2003) (1023)
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (2012) (985)
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas (1990) (954)
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B (1995) (838)
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer (2002) (749)
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) (611)
BAY 43-9006 inhibition of oncogenic RET mutants. (2006) (480)
MicroRNA deregulation in human thyroid papillary carcinomas. (2006) (418)
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases (1987) (403)
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. (2007) (395)
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. (1992) (391)
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. (1994) (376)
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (2007) (363)
Mutation of the PIK3CA gene in anaplastic thyroid cancer. (2005) (336)
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. (1998) (329)
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. (2005) (322)
High level expression of the HMGI (Y) gene during embryonic development. (1996) (315)
The RET receptor: function in development and dysfunction in congenital malformation. (2001) (288)
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. (1989) (282)
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. (2004) (278)
RET/PTC oncogene activation is an early event in thyroid carcinogenesis. (1995) (270)
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. (2013) (261)
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. (1998) (260)
Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's Thyroiditis (1997) (255)
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. (1999) (255)
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* (2006) (251)
Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. (1996) (249)
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. (1990) (246)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors (2004) (238)
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. (1992) (235)
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. (1994) (232)
The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. (1999) (213)
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2002) (211)
Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells (1995) (210)
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. (2006) (198)
The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. (1995) (198)
Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression (1997) (197)
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. (2004) (194)
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. (2006) (187)
New therapeutic approaches to treat medullary thyroid carcinoma (2008) (184)
Mast cells have a protumorigenic role in human thyroid cancer (2010) (184)
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma (2006) (182)
Targeting the RET Pathway in Thyroid Cancer (2009) (181)
Minireview: RET: normal and abnormal functions. (2004) (176)
Molecular Mechanisms of RET Activation in Human Cancer (2002) (169)
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. (2007) (166)
Neoplastic transformation of rat thyroid cells requires the junB and fra‐1 gene induction which is dependent on the HMGI‐C gene product (1997) (163)
Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. (1996) (160)
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway (2015) (159)
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. (2004) (155)
Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. (1998) (154)
PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 (2000) (153)
RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid (2000) (148)
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. (2002) (146)
Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade (2001) (145)
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. (1996) (145)
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. (2002) (144)
The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. (1993) (143)
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret (1998) (139)
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. (2004) (139)
Inhibitory Effects of Peroxisome Proliferator-Activated Receptor γ on Thyroid Carcinoma Cell Growth (2002) (139)
NCOA4 Deficiency Impairs Systemic Iron Homeostasis. (2016) (136)
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas (2004) (134)
Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers (1994) (132)
Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts (1998) (132)
Developmental expression of the RET protooncogene. (1994) (131)
Gene rearrangement and Chernobyl related thyroid cancers (2000) (126)
An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway (1994) (125)
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts (2011) (123)
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). (2003) (121)
Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1 (2000) (120)
RET activation and clinicopathologic features in poorly differentiated thyroid tumors. (2002) (115)
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas (2005) (114)
Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines (1998) (114)
The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium (2000) (112)
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. (2007) (111)
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. (2007) (111)
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (2002) (111)
The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. (2002) (106)
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. (2009) (103)
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway (2001) (103)
Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer (2005) (102)
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. (1997) (102)
Transplantation of Germ Cells from Glial Cell Line-Derived Neurotrophic Factor-Overexpressing Mice to Host Testes Depleted of Endogenous Spermatogenesis by Fractionated Irradiation1 (2002) (101)
Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation (2001) (95)
Dysfunction of the RET receptor in human cancer. (2004) (94)
High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth (2001) (93)
Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine growth factors stimulating DNA synthesis of Ret-expressing spermatogonia. (2000) (93)
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. (2000) (92)
A Novel Member of the BTB/POZ Family, PATZ, Associates with the RNF4 RING Finger Protein and Acts as a Transcriptional Repressor* (2000) (92)
Central role of RET in thyroid cancer. (2013) (92)
Thyroid cell transformation requires the expression of the HMGA1 proteins (2002) (92)
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. (2007) (86)
The Neuron-Specific Rai (ShcC) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway (2002) (85)
The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. (2009) (84)
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. (2005) (83)
The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. (1998) (83)
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. (2013) (82)
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. (2005) (82)
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. (2001) (77)
Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer (2006) (77)
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells (2010) (77)
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. (2007) (76)
The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret (2001) (76)
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. (2010) (76)
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. (1993) (75)
RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. (2002) (75)
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. (1995) (74)
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. (1992) (74)
Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. (2003) (74)
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. (2009) (74)
Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants (2007) (73)
Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors (2003) (72)
Co‐segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss‐of‐function? (1999) (72)
Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). (2010) (70)
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas (2006) (70)
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. (2008) (69)
HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. (2008) (68)
Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line (1995) (68)
Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. (2014) (67)
Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer (2005) (66)
Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. (1999) (66)
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway (2009) (65)
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model (2013) (64)
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma (2007) (64)
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells (2003) (64)
Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo (1998) (64)
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. (2003) (64)
Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. (1994) (63)
The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). (1989) (63)
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. (2012) (62)
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. (2009) (62)
Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. (1998) (62)
Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. (2001) (62)
Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. (1997) (62)
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane (2001) (61)
High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases (2001) (61)
Dysregulated RET signaling in thyroid cancer. (2008) (59)
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. (2007) (59)
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. (1996) (58)
Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. (2000) (58)
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. (1995) (58)
Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells (2010) (57)
RET Gene Fusions in Malignancies of the Thyroid and Other Tissues (2020) (56)
RNF4 is a growth inhibitor expressed in germ cells but not in human testicular tumors. (2001) (56)
The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. (2002) (55)
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (2016) (55)
Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness (2005) (54)
Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. (1997) (54)
Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells (2004) (54)
Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. (2002) (53)
Ret-mediated mitogenesis requires Src kinase activity. (1999) (53)
FRA-1 expression in hyperplastic and neoplastic thyroid diseases. (2000) (53)
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes (2003) (52)
Thymosin β-10 Gene Overexpression Correlated with the Highly Malignant Neoplastic Phenotype of Transformed Thyroid Cells in Vivo and in Vitro (1998) (52)
Simian virus 40-like DNA sequences in human papillary thyroid carcinomas (1998) (51)
RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association. (2014) (51)
The Adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. (1993) (50)
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. (2011) (50)
Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation. (1992) (50)
Extracellular superoxide dismutase is a growth regulatory mediator of tissue injury recovery. (2009) (49)
Cooperation between the polyomavirus middle-T-antigen gene and the human c-myc oncogene in a rat thyroid epithelial differentiated cell line: model of in vitro progression (1988) (49)
A mutated p53 gene alters thyroid cell differentiation. (1995) (49)
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells (2004) (49)
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. (2014) (48)
Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation* (2013) (47)
Establishment of a non‐tumorigenic papillary thyroid cell line (FB‐2) carrying the RET/PTC1 rearrangement (2002) (46)
Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas (2001) (46)
Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. (1996) (46)
Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? (1999) (46)
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. (2006) (45)
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. (2018) (45)
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. (2005) (44)
The importance of the RET gene in thyroid cancer and therapeutic implications (2021) (44)
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. (2004) (44)
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho (2001) (44)
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. (2011) (42)
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. (2018) (42)
Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene* (2006) (42)
A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. (1996) (42)
Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. (2013) (42)
XB130 Mediates Cancer Cell Proliferation and Survival through Multiple Signaling Events Downstream of Akt (2012) (41)
Receptor tyrosine kinase inhibitors in thyroid cancer. (2008) (40)
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas (2012) (40)
Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. (1991) (39)
Molecular mechanisms of RET activation in human neoplasia (1999) (39)
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. (1998) (39)
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. (2008) (39)
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome (2007) (39)
Oncogenes and Thyroid Cancer (2000) (39)
20 years of RET/PTC in thyroid cancer: clinico-pathological correlations. (2007) (38)
A new mechanism of BRAF activation in human thyroid papillary carcinomas. (2005) (38)
Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. (2018) (37)
RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors (2005) (37)
A novel de novo germ‐line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization (2009) (37)
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. (2012) (36)
Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. (1999) (36)
Protein kinase Cα activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase (2003) (36)
The Kirsten murine sarcoma virus induces rat thyroid carcinomas in vivo. (1989) (35)
A novel pathway of cell growth regulation mediated by a PLA2α‐derived phosphoinositide metabolite (2006) (35)
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 (2010) (35)
Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. (2011) (35)
Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. (2000) (35)
SOD3 Decreases Ischemic Injury Derived Apoptosis through Phosphorylation of Erk1/2, Akt, and FoxO3a (2011) (35)
Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. (2008) (34)
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. (2015) (34)
Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. (1995) (33)
A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. (2003) (33)
Identification and characterization of a novel RING-finger gene (RNF4) mapping at 4p16.3. (1998) (32)
Rat protein tyrosine phosphatase η physically interacts with the PDZ domains of syntenin (2001) (32)
Identification of RET Kinase Inhibitors as Potential New Treatment for Sporadic and Inherited Thyroid Cancer (2004) (30)
Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer. (2010) (30)
A TSH-CREB1-microRNA loop is required for thyroid cell growth. (2011) (30)
High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. (2001) (30)
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma (2014) (29)
Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. (1996) (29)
Loss of p27 Expression Through RAS->BRAF->MAP Kinase-Dependent Pathway in Human Thyroid Carcinomas (2007) (29)
HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. (2003) (29)
Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis. (2003) (29)
Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. (1995) (28)
Update: the status of clinical trials with kinase inhibitors in thyroid cancer. (2014) (28)
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. (2008) (28)
Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. (1998) (27)
CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. (2010) (27)
Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. (2009) (26)
Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies (2014) (26)
Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. (1994) (25)
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells (2014) (25)
Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas (2005) (25)
Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. (1998) (24)
Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin (2004) (24)
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC. (2010) (24)
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. (2010) (23)
The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (2005) (23)
Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases (2012) (23)
In Vivo and in Vitro Characterization of a Novel Germline RET Mutation Associated with Low-Penetrant Nonaggressive Familial Medullary Thyroid Carcinoma (2006) (22)
Presence of physiologically stimulated RET in adult rat brain: induction of RET expression during nerve regeneration. (1996) (22)
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. (2017) (22)
Morphological ultrasound microimaging of thyroid in living mice. (2009) (22)
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. (2016) (21)
Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. (2012) (21)
Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. (2008) (21)
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27kip 1 (2002) (19)
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase (2015) (19)
Molecular Cloning of PTC, a New Oncogene Found Activated in Human Thyroid Papillary Carcinomas and Their Lymph Node Metastases a (1988) (19)
Molecular biomarkers in thyroid FNA samples. (2012) (18)
Erratum: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells (American Society for Clinical Investigation (2005) 115:4 (1068-1081) DOI: 10.1172/JCI22758) (2016) (18)
Receptor tyrosine kinases as targets for anticancer therapeutics. (2005) (18)
Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis. (2000) (17)
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. (2014) (16)
Different mutations of the RET gene cause different human tumoral diseases. (1999) (16)
Protein tyrosine phosphatase-eta expression is upregulated by the PKA-dependent and is downregulated by the PKC-dependent pathways in thyroid cells. (1998) (16)
The high transforming potency of erbB-2 and ret is associated with phosphorylation of paxillin and a 23 kDa protein. (1994) (16)
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. (2009) (16)
A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma (2017) (16)
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology (2020) (15)
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. (2002) (15)
Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1* (2016) (15)
Ligand Stimulation of a Ret Chimeric Receptor Carrying the Activating Mutation Responsible for the Multiple Endocrine Neoplasia Type 2B* (1996) (15)
Thyroid cancer in 2010: A roadmap for targeted therapies (2011) (15)
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. (1997) (15)
Is Co-option a prevailing mechanism during cancer progression? (2011) (15)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2018) (14)
Cytosolic Phospholipase A2α Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells (2007) (14)
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability (2016) (13)
The Kinase Inhibitor PP 1 Blocks Tumorigenesis Induced by RET Oncogenes 1 (2002) (13)
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. (2021) (13)
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. (2000) (12)
Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready? (2010) (12)
Genetics: The genomic landscape of papillary thyroid carcinoma (2015) (12)
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. (2006) (12)
Pivotal role of the RB family proteins in in vitro thyroid cell transformation. (2000) (11)
The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (2005) (11)
Activated RET oncogene products induce maturation of xenopus oocytes. (1995) (10)
Oncogenic rearrangements driving ionizing radiation-associated human cancer. (2013) (10)
Regulation of thymosin beta10 expression by TSH and other mitogenic signals in the thyroid gland and in cultured thyrocytes. (1999) (10)
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). (2002) (9)
Medullary thyroid carcinomas in transgenic mice expressing a Polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens (1999) (9)
The ret protooncogene is expressed in normal human parafollicular thyroid-cells. (1994) (9)
Regulation of p 27 Kip 1 Protein Levels Contributes to Mitogenic Effects of the RET / PTC Kinase in Thyroid Carcinoma Cells (2004) (8)
Oncogenic protein tyrosine kinases (2004) (7)
Receptor- and Non-Receptor Tyrosine Kinases Induce Processing of the Amyloid Precursor Protein: Role of the Low-Density Lipoprotein Receptor-Related Protein (2007) (7)
Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia (2018) (7)
TPA induces a block of differentiation and increases the susceptibility to neoplastic transformation of a rat thyroid epithelial cell line. (1998) (7)
The tyrosine kinase inhibitor ZD 6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells (2010) (7)
New drugs in thyroid cancer. (2007) (7)
Cytosolic phospholipase A2 alpha regulates cell growth in RET/PTC-transformed thyroid cells. (2007) (6)
CaV 2 . 3 channel and PKC λ : new players in insulin secretion (2004) (6)
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms. (2019) (6)
Thyroid cancer: A molecular perspective (2010) (5)
Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice. (2001) (5)
Overexpression of Proteins HMGA 1 Induces Cell Cycle Deregulation and Apoptosis in Normal Rat Thyroid Cells 1 (2001) (5)
EXTENSIVE CLINICAL EXPERIENCE Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma (2007) (5)
Impairment of the p 27 kip 1 function enhances thyroid carcinogenesis in TRK-T 1 transgenic mice (2009) (5)
CD 44 Proteolysis Increases CREB Phosphorylation and Sustains Proliferation of Thyroid Cancer Cells (2012) (5)
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma (2007) (4)
Norepinephrine and thyrotropin stimulation of [Ca++]i in PC C13 a rat thyroid epithelial cell line: effect of transformation by E1A gene adenovirus and polyomavirus middle-T antigen gene. (1993) (4)
NCOA4 links iron bioavailability to DNA metabolism. (2022) (4)
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases (2021) (4)
Ret-mediated Mitogenesis Requires Src Kinase Activity 1 (1999) (3)
Structure and Chemical Inhibition of the RET Tyrosine (2006) (3)
Circulating long non-coding RNA signature in knee osteoarthritis patients with postoperative pain one-year after total knee replacement (2021) (3)
Association between the expression of E1A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells. (2000) (3)
Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. (2005) (2)
RFLP for TaqI of the human thyroid papillary carcinoma (PTC) oncogene. (1988) (2)
Association between the expression of E 1 A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells (2000) (2)
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. (2009) (2)
Pros and cons of cellular studies in developing new drugs for thyroid cancers. (2008) (2)
Retraction for Berlingieri et al., “Inhibition of HMGI-C Protein Synthesis Suppresses Retrovirally Induced Neoplastic Transformation of Rat Thyroid Cells” (2018) (1)
Endocannabinoids as emerging suppressors of angiogenesis and breast tumor growth and metastatic spreading ” (2008) (1)
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells (2014) (1)
The ret protooncogene is expressed in predominantly epithelial human thymomas. (1994) (1)
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. (2022) (1)
Docetaxel in adjuvant therapy of breast cancer : results of the TAXIT 216 multicenter phase III trial ” (2008) (1)
thyroid carcinogenesis in TRK-T1 transgenic mice (2009) (1)
1505: Ultrasound Micro-Imaging of Thyroid in Living Mice (2009) (1)
Pathogenesis of Thyroid Carcinoma (2016) (1)
Attacking cancer with molecularly targeted agents. (2013) (1)
Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas. (2003) (1)
Thyroid Neoplastic Transformation In Vitro and In Vivo (1984) (1)
Identification of a Chimeric Gene Frequently Activated in Human Thyroid Papillary Carcinomas (1993) (1)
Intracellular Signaling by the ret Tyrosine Kinase (1996) (1)
The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture (1992) (1)
The RET Receptor Family (2015) (1)
SymposiumRole of oncogene activation in human thyroid carcinomas (1990) (1)
Control of breast cancer cell growth by adipocyte-released factors ” (2009) (1)
Activation of the ret oncogene in human thyroid carcinomas (1993) (1)
RET: A Multi-Faceted Gene in Human Cancer (2012) (1)
Inside Back Cover: Fragment‐Based Discovery of a Dual pan‐RET/VEGFR2 Kinase Inhibitor Optimized for Single‐Agent Polypharmacology (Angew. Chem. Int. Ed. 30/2015) (2015) (0)
Glial cell line-derived nenrotrophic factor (GDNF) stimulates ret activity (1997) (0)
statementregardingthepossibilityofsuchanadverseeventisincluded onthevandetaniblabel,andthereisarequirementthateachphysician who prescribes vandetanib (in the United States) complete an educa- tional program that addresses the risks of QTc prolongation. (2012) (0)
Retraction: Suppression of HMGA2 Protein Synthesis Could Be a Tool for the Therapy of Well Differentiated Liposarcomas Overexpressing HMGA2. (2018) (0)
Patologia. - Glial cell line-derived neurotrophic factor (GDNF) stimulates ret activity (1997) (0)
Role of the calcium-calmodulin dependent kinase 2 in medullary thyroid carcinoma (2013) (0)
Medullary Thyroid Cancer Cells inCalcitonin Gene Expression through Distinct Mechanisms The RET Kinase Inhibitor NVP-AST 487 Blocks Growth and Updated (2007) (0)
Retraction: The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. (2018) (0)
Malignant Phenotype in Thyroid Cancer Gene Expression Correlates with a Highly CBX 7 Loss of the Updated (2008) (0)
Human Cancer Biology Activationof themTORPathway inPrimaryMedullary Thyroid Carcinoma and Lymph Node Metastases (2012) (0)
New findings in growth factor receptors and integrins cross-talk (2003) (0)
Signaling Pathway to the Phosphatidylinositol 3-Kinase / Akt Protein Inhibits Apoptosis by Coupling Ret ) Adaptor ShcC ( Rai The Neuron-Specific (2002) (0)
Retraction for Trapasso et al., “Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1” (2018) (0)
Thymosin ÃŸ-10Gene Overexpression Correlated with the Highly Malignant Neoplastic Phenotype of Transformed Thyroid Cells in Vivo and in Vitro1 (2006) (0)
Molecular and genetic alterations in human thyroid carcinomas (1997) (0)
Molecular mechanisms in thyroid cancer (2010) (0)
Effect of viral oncogenes transformation on TSH- and norepinephrine-evoked [Ca++]i increase in rat thyroid cells (1992) (0)
RON IS A HETERODIMERIC TYROSINE KINASE RECEPTOR ACTIVATED BY THE HGF HOMOLOG MSP / G. GAUDINO; A. FOLLENZI; L. NALDINI; C. COLLESI; M. SANTORO; (0)
Correction to: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2022) (0)
The role of autophagy in neoplastic cell response to oncolytic viruses ” (2009) (0)
Doctorate Program in Molecular Oncology and Endocrinology (2006) (0)
Osteopontin Expression Predicts the Clinical Outcome of Laryngeal Intraepithelial Neoplasia (2007) (0)
RET Recognition of GDNF-G FR a 1 Ligand by a Composite Binding Site Promotes Membrane-Proximal Self-Association Graphical (2014) (0)
Patologia. -- Glial Ceil Line-Derzved Neurotrophic Factor (GDNF) stimulates Ret activity. Nota di FRANCESCA CARLOMAGNO, ROSA MARINA MELILLO, GIULIANA SALVATORE, (1997) (0)
New genes involved in the neoplastic transformation of the thyroid gland (2006) (0)
ActivationofthemTORPathwayinPrimaryMedullaryThyroid Carcinoma and Lymph Node Metastases (2012) (0)
RECEPTOR TYROSINE KINASES AS TARGET FOR ANTI-CANCER THERAPY RECEPTOR TYROSINE KINASES AS TARGET FOR ANTI-CANCER THERAPY (0)
Downregulation of Alpha‐L‐Fucosidase Expression Is Related to Dedifferentiation and Worse Prognosis in Thyroid and Breast Cancer. (2016) (0)
Gene expression profile analysis of pituitary adenomas developed by HMGA transgenic mice ” (2007) (0)
Detection ofRET oncogeneactivation inhumanpapillary thyroid carcinomas byinsitu hybridisation (1992) (0)
Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck ” (2008) (0)
Molecular and Cellular Pathobiology CD 44 Proteolysis Increases CREB Phosphorylation and Sustains Proliferation of Thyroid Cancer Cells (2012) (0)
a Potential Diagnostic Indicator of Carcinoma Diagnosis of Thyroid Tumors : HMGI ( Y ) Expression Represents Detection of High Mobility Group I HMGI ( Y ) Protein in the Updated Version (2006) (0)
New biomolecular prognostic and predictive factors of response to treatments in colorectal cancer ” (2010) (0)
Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. (2020) (0)
Sulfate-binding Protein in Human Thyroid Carcinomas Gene Coding for a Heparin / Heparan HIP Overexpression of the Updated (2006) (0)
Calcium-calmodulin dependent kinase II is activated by mutated RET in medullary thyroid carcinoma (2010) (0)
Pathogenesis of Thyroid Cancer (2021) (0)
Retraction: FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases (2019) (0)
The Cooperation between Viral ras Genes and Different Immortalizing Genes Induces the Transformation of Rat Thyroid Epithelial Cells (1989) (0)
Molecular pathogenesis of MTC: Role of RET oncogene (2012) (0)
45th Annual Meeting of the Italian Cancer Society Bergamo, 9-12 November 2003 (2004) (0)
PTC in thyroid tumours (1993) (0)
Molecular mechanisms of insulin resistance : role of endocannabinoid system in the regulation of glucose metabolism and insulin action ” (2007) (0)
Ribonucleases as antitumor agents (2003) (0)
Absence of Dedifferentiating and Transforming Effects Hormone-independent Proliferation of Thyroid Cells in the Akt / Protein Kinase B Promotes Survival and Updated (2000) (0)
Roles of mast cells and their mediators in human thyroid carcinomas (2007) (0)
A novel pathway of cell growth regulation mediated by a PLA 2 (cid:1) -derived phosphoinositide metabolite (2006) (0)
Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab (2012) (0)
Developmental Expression of the RET Protooncogene 1 (2005) (0)
Innenrücktitelbild: Fragment‐Based Discovery of a Dual pan‐RET/VEGFR2 Kinase Inhibitor Optimized for Single‐Agent Polypharmacology (Angew. Chem. 30/2015) (2015) (0)
PTC oncogenic signaling through the Rap 1 small GTPase (2013) (0)
Retraction for Melillo et al., “Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation” (2018) (0)
Reply to J.-F. Chatal et al (2012) (0)
Molecular Pathways Targeting the RET Pathway in Thyroid Cancer (2009) (0)
Indoleamine 2,3-dioxygenase 1 (IDO1) and thyroid carcinoma: Ret/PTC appears as a strong genetic determinant for IDO1 expression (2012) (0)
ergistic Antitumor Activity of Sorafenib in Combination Epidermal Growth Factor Receptor Inhibitors in R orectal and Lung Cancer Cells (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Massimo Santoro?

Massimo Santoro is affiliated with the following schools:

Massimo Santoro's Academic­Influence.com Rankings

Why Is Massimo Santoro Influential?

Massimo Santoro's Published Works

Published Works

What Schools Are Affiliated With Massimo Santoro?

Massimo Santoro's AcademicInfluence.com Rankings